If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
20/08/2026 [07:52:00]
Results 125 to 138 of 138
Absstract of: ES3055703A1
Biomarkers of inflammatory bowel diseases. The present invention relates to a method for early determination of whether a subject has an inflammatory bowel disease, comprising determining the expression product level of at least one biomarker, from a biological sample of a subject, selected from: ATRN, PRDX4, MOAB and AZU1. (Machine-translation by Google Translate, not legally binding)
Absstract of: WO2026034527A1
Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and/or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.
Absstract of: WO2024206308A2
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Absstract of: WO2024200594A1
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Absstract of: CN121499685A
The invention discloses a multi-index content determination method of hovenia acerba and rhizoma atractylodis bowel-relaxing granules, and belongs to the technical field of traditional Chinese medicine detection. The invention establishes a high performance liquid chromatography method for simultaneously determining nine components including caffeic acid, chicoric acid, naringin, naringin, hesperidin, neohesperidin, chrysophanol, aurantio-obtusin and atractylenolide I in a preparation, and the content of the components is calculated through a relative correction factor by taking caffeic acid as an internal reference by adopting a quantitative analysis of multi-components by single marker. According to the method, effective detection of the immature bitter orange medicinal material and the immature bitter orange base source is realized, and the immature bitter orange and the sweet orange base source of the traditional Chinese medicine immature bitter orange can be accurately distinguished, so that more comprehensive and accurate quality control of the traditional Chinese medicine is realized, and the stability and consistency of clinical efficacy of the traditional Chinese medicine are guaranteed.
Absstract of: EP4417707A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Absstract of: CN121472476A
The invention discloses a citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis. According to the invention, a genome typing technology in a whole genome range is adopted, and a set of discrimination system capable of accurately identifying real hybrid offspring is established through high-density SNP (Single Nucleotide Polymorphism) marker analysis and an IBD (Identity by means of an algorithm. The method breaks through the limitation of a traditional method on hybrid filial generation identification, and provides reliable technical support for breeding practice.
Absstract of: WO2026027669A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Absstract of: US20260036584A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Absstract of: WO2026027676A1
Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.
Absstract of: CN121454070A
本发明公开了琥珀酸对坏死性小肠结肠炎影响机制的研究方法，涉及生物医学研究技术领域；包括如下步骤：S1：动物模型建立：选择新生小鼠，随机分为4组；S2：干预周期：持续处理3‑5天，每日记录体重、存活率及存活状态；S3：样本采集：处死小鼠，取肠组织，分装用于不同检测；S4：多维度检测；S5：数据分析：整合表型、病理、分子数据，验证琥珀酸‑SUCNR1轴的功能。本发明构建了完整的研究琥珀酸‑SUCNR1轴在坏死性小肠结肠炎中作用机制的技术体系，通过动物模型构建、分子机制验证和病理评估的有机结合，形成了从现象观察到机制阐明的完整证据链，确保研究结论的可靠性。
Absstract of: CN121445742A
本发明涉及双氢麦角胺在制备预防和/或治疗炎症性肠病的药物中的应用。本发明在炎症性肠病模型中验证得出一种全新的作用机制：炎症条件下TRIM25会介导LSD1的泛素化降解，引起肠上皮组织代谢紊乱加剧炎症。本发明通过预测TRIM25和LSD1结合的结构信息，使用虚拟药物筛选，筛到了双氢麦角胺小分子化合物，其可很好地占据TRIM25和LSD1互作的结合位点，抑制TRIM25和LSD1的互作，从而抑制LSD1的降解；在DSS诱导的小鼠结肠炎模型中，双氢麦角胺能缓解肠上皮因代谢紊乱造成的炎症激活，很好地缓解炎症性肠病的症状。上述过程作用机制明确，效果显著，实现了双氢麦角胺在治疗炎症性肠病方面的老药新用，具有较高的临床应用价值。
Nº publicación: IL325135A 01/02/2026
Applicant:
DIASORIN ITALIA S P A [IT]
CLAUDIA ZIEROLD
FABRIZIO BONELLI
MARIA ASSUNTA PALMIERI
CLAUDIO MASTRONARDO
DIASORIN ITALIA S.P.A.
Claudia ZIEROLD
Fabrizio BONELLI
Maria Assunta PALMIERI
Claudio MASTRONARDO
Absstract of: WO2024252267A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
BOPI
Electronic site
